Simplify Asset Management Inc. Makes New Investment in Ascendis Pharma A/S (NASDAQ:ASND)

Simplify Asset Management Inc. bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,877 shares of the biotechnology company’s stock, valued at approximately $1,211,000.

Several other hedge funds have also recently bought and sold shares of the business. Seven Eight Capital LP increased its holdings in shares of Ascendis Pharma A/S by 245.4% in the 2nd quarter. Seven Eight Capital LP now owns 15,876 shares of the biotechnology company’s stock valued at $2,165,000 after purchasing an additional 11,279 shares during the period. Massachusetts Financial Services Co. MA raised its position in Ascendis Pharma A/S by 5.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock valued at $233,348,000 after acquiring an additional 93,185 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in Ascendis Pharma A/S by 42.0% during the second quarter. Oppenheimer Asset Management Inc. now owns 6,927 shares of the biotechnology company’s stock valued at $945,000 after acquiring an additional 2,048 shares in the last quarter. First Turn Management LLC lifted its stake in Ascendis Pharma A/S by 23.1% in the second quarter. First Turn Management LLC now owns 186,581 shares of the biotechnology company’s stock valued at $25,446,000 after acquiring an additional 34,994 shares during the last quarter. Finally, Headlands Technologies LLC bought a new stake in Ascendis Pharma A/S in the second quarter worth approximately $864,000.

Ascendis Pharma A/S Trading Up 3.1 %

Shares of NASDAQ ASND opened at $153.43 on Friday. Ascendis Pharma A/S has a 1-year low of $85.29 and a 1-year high of $161.00. The company has a 50-day moving average of $132.94 and a two-hundred day moving average of $136.52. The company has a market cap of $8.93 billion, a PE ratio of -15.97 and a beta of 0.63.

Wall Street Analyst Weigh In

ASND has been the subject of several analyst reports. The Goldman Sachs Group lifted their price objective on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. lowered their price objective on Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating on the stock in a report on Wednesday, September 4th. Wells Fargo & Company boosted their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research note on Tuesday. Citigroup increased their target price on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Jefferies Financial Group boosted their target price on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research report on Tuesday, August 13th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $193.77.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.